The National Eye Institute (NEI) recently launched the first-ever human gene therapy trial for the vision disorder X-linked retinoschisis (XLRS). Researchers are conducting the trial at the National Institutes of Health Clinical Research Center in Bethesda, Maryland.
People are bad at staying focused. We’ve all had our minds wander when we try to concentrate on a task that requires paying close attention but isn’t all that engaging. But a new NIH-funded study suggests that one’s capacity to stay focused can improve with real-time feedback.
In an NIH-supported clinical trial comparing three drugs for diabetic macular edema (DME), Eylea (aflibercept) provided greater visual improvement, on average, than did Avastin (bevacizumab) or Lucentis (ranibizumab) when vision was 20/50 or worse at the start of the trial.
News from NEI Grantees
- 3D structure solved for vulnerable region of glaucoma-causing protein April 21, 2015
- Stem Cell Injection May Soon Reverse Vision Loss Caused By Age-Related Macular Degeneration April 15, 2015
- One test can predict which kids will become nearsighted April 2, 2015
- LSU Health New Orleans Makes Discovery Key to Preventing Blindness and Stroke Devastation Posted on March 9, 2015
- Results challenge conventional wisdom about where the brain begins processing visual information Posted on March 2, 2015
- Stem Cells from Wisdom Teeth Can Be Transformed into Corneal Cells–Could Potentially Be Used to Treat Corneal Scarring Posted on February 23, 2015
- Tufts University Researchers Identify Mechanism Involved in Causing Cataracts in Mice Posted on January 12, 2015
- View all News from NEI Grantees
Budget and Congress
The NEI budget is approximately $675 million (FY2014). The NEI budget requests are submitted to Congress with other NIH institutes as part of the President’s budget request in February. See our Congressional Justifications.